Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc., a Delaware corporation, on October 30, 2025, reporting events occurring on October 28, 2025. The company is listed on The Nasdaq Capital Market under the symbol COCP.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than standard periodic financial results. Key metrics from the transaction include:
- Gross Proceeds: $1.03 million
- Securities Issued: 739,426 units
- Price Per Unit: $1.39
- Unit Composition: One share of common stock and one warrant to purchase two shares of common stock.
- Warrant Terms: Exercise price of $1.24 per share; 27-month term.
- Investors: Four accredited investors, all of whom are insiders of the Company.
The filing does not provide data on revenue, profit, operating cash flow, margins, total debt, or liquidity positions as this is a transaction-specific report.
Material Changes
The primary material change is the increase in outstanding equity securities and the influx of $1.03 million in cash proceeds from the sale of unregistered units to insiders. No other material changes to the company's financial condition or operations are disclosed in this filing.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors beyond the standard disclosure that the press release information is not deemed "filed" under Section 18 of the Exchange Act. The transaction was exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Key Facts for Investor Verification
- Verify the dilution impact of 739,426 new shares plus the potential issuance of up to 1,478,852 additional shares upon full warrant exercise.
- Confirm the identity of the four insider purchasers to assess potential conflicts of interest or strategic alignment.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for any covenants or restrictions not summarized in the 8-K.
- Check subsequent filings for the use of the $1.03 million in proceeds.